



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

January 15, 2008 6:30 – 9:00 p.m. **PLEASE NOTE DATE**

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meetings** **7:20 - 7:30**
 - Diabetic Testing Supplies
 - OVHA Pharmacy Bulletin: Buprenorphine PA Process, Diabetic Testing Supply PDL Changes
 - CellCept®/Myfortic® Communication to Prescribers
 - Erythropoiesis Stimulating Agents Communication to Prescribers (and new FDA News Release – Risk of Anemia Drugs)
 - OVHA Pharmacy Bulletin: Summary of PDL Changes for 01/01/08
- 6. Clinical Update: Drug Reviews** **7:30 – 7:45**

(Public comment prior to Board action)

 - Neupro® Patch (rotigotine)
 - Seroquel® XR (quetiapine)
 - Vyvanse® (lisdexamfetamine)
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:45 – 8:20**

(Public comment prior to Board action)

Criteria Changes

 - Anticonvulsants (Lyrica® in fibromyalgia)
 - Anti-diabetics: Insulin
 - Anti-Infectives: Influenza Vaccines
 - BPH: Androgen Hormone Inhibitors
 - Cough and Cold Preparations
 - Pulmonary: Antihistamines: 1st Generation

Preferred Product Changes

 - Anti-hyperkinesia and Anti-Narcolepsy (and quantity limits)
 - Anti-Infectives: Genital Antivirals

8. Drug Classes – New	8:20 – 8:25
▪ Gastrointestinals: Inflammatory Bowel Agents	
9. RetroDUR	8:25 - 8:40
▪ Marinol®	
▪ Mental Health Medication Use in Children	
10. New Drug Product Plan Exclusions (Consent Agenda Topic)	8:40 - 8:45
11. Updated New-to-Market Drug Monitoring Log	8:45 - 8:50
12. General Announcements	8:50 - 9:00
FDA Safety Alerts	
▪ Desmopressin Acetate – severe hyponatremia and seizures	
▪ Fentanyl Transdermal System – death and overdose	
▪ Bisphosphonates – severe bone, joint, and/or muscle pain	
13. Adjourn	9:00